Author

Estella T. Mendelson

Observed names: E. Mendelson, E.T. Mendelson, Estella Mendelson

Observed institution: Novartis (United States)

OpenAlex ID: A5058952186

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

2013 · Claire N. Harrison, Ruben A. Mesa, et al. · British Journal of Haematology · 90

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

2015 · Keith L. Davis, Isabelle Côté, et al. · Advances in Hematology · 28

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

2014 · Carla Maria Boquimpani, Tomasz Szczudlo, et al. · Blood · 21

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

2013 · Matthew Squires, Claire N Harrison, et al. · Blood · 18

Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

2019 · Jorge Cortes, Lynn Huynh, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15

Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent

2017 · Paul Richardson, Anuja Roy, et al. · Expert Review of Hematology · 11

Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective

2012 · Khalid El Ouagari, Christopher John Knight, et al. · Blood · 9

Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study.

2012 · Jean-Jacques Kiladjian, Heinz Gisslinger, et al. · Journal of Clinical Oncology · 9

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

2011 · Ruben A. Mesa, Srdan Verstovsek, et al. · Blood · 7

Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib

2014 · Keith L Davis, James A. Kaye, et al. · Blood · 5

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

2011 · Claire N. Harrison, Jean-Jacques Kiladjian, et al. · Blood · 4

PCN95 Using a Condition-Specific Measure of Patient-Reported Outcomes to Derive Utilities in Myelofibrosis

2012 · N.S. Roskell, E.T. Mendelson, et al. · Value in Health · 3

Pcn328 Understanding of Patient Experience With Diffuse Large B-cell Lymphoma (dlbcl) Through Social Media Listening

2020 · E. Mendelson, J. Nast, et al. · Value in Health · 2

Treatment Characteristics and Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study

2017 · Jorge E. Cortés, Lynn Huynh, et al. · Blood · 1

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

2015 · Giuseppe Saglio, Sonya J. Snedecor, et al. · Blood · 1

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

2015 · Francois-Xavier Mahon, An Tran-Duy, et al. · Blood

Works count: 16

Citation count: 224

H-index: 8

I10-index: 6